Jul 1, 2011
By:
William Looney
More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them
|
Jul 1, 2011
By:
William Looney
Pfizer's crizotinib development program combined organization, art, and science—and a large dose of unforeseen risk
|
|
Call it spit and risk—hitting it
Jun 1, 2011
By:
William Looney
With Yankee stadium as the backdrop, Pharm Exec convened its annual panel of eight business development experts to crack the bat on best practice in licensing and M&A for the year ahead.
|
|
Jun 1, 2011
By:
William Looney
Now that government payers are turning to pharma to bridge budgetary shortfalls it's best to think long-term
|
|
May 1, 2011
By:
William Looney
What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
|
Apr 1, 2011
By:
William Looney
Dutch-based DSM N.V. is seeking innovatinve ways to partner through bolstering manufacturing
|
Apr 1, 2011
By:
William Looney
A true performance culture has to focus on the mundane as much as the sublime
|
|
Apr 1, 2011
By:
William Looney
Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry
|
|
Will reinforced evidence and messaging continue to deliver results in a changing healthcare marketplace? Can PhRMA's own business model synch with industry's? Pharm Exec takes a closer look at PhRMA's new leadership
Mar 1, 2011
By:
William Looney
Can PhRMA's own business model synch with industry's Pharm Exec takes a closer look at PhRMA's new leadership.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
